News
Melissa Snover brings 3D-printed personalised nutrition to SXSW 2025
What if your daily nutrition could be personalised, 3D-printed, and tailored to your exact needs—on demand?
At SXSW 2025, award-winning entrepreneur and industry disruptor Melissa Snover will take the stage to discuss how personalised health and cutting-edge technology are transforming the future of wellness.
Melissa will take the stage at UK House, Palm Door… as part of TechWM’s ‘Peaky Pioneers: The Midlands Takeover’, delivering a spotlight talk on the revolution happening in personalised wellness.
With over 20 years of entrepreneurial success and several successful exits, Melissa has established a strong track record for innovation and brand-building on a global scale.
She is a registered nutritionist and one of ten members of the Department for Business and Trade’s inaugural Female Founders initiative to boost investment in women-led tech businesses.
For decades, the supplement industry has been built on mass-market solutions that fail to recognise individual differences in lifestyle, genetics, and health goals.
Melissa will explain why customisation is the future of health and how Nourished is already leading this transformation with 3D-printed, tailor-made nutrition stacks and highly targeted products for specific needs, goals and lifestyles.
Melissa will join an exclusive panel discussion at 4PM called ‘Make it in Creative and Tech: From the Midlands to the World,” appearing alongside the Managing Director at Orlo and Partner and Co-Founder at ATXponential.
The discussion, chaired by Yiannis Maos MBE, CEO of Tech West Midlands, will explore the opportunities between the UK and US and why forging transatlantic partnerships can supercharge growth.
Alongside these highly anticipated speaking engagements, Nourished will be showcasing its live 3D-printing technology at UK House @ Palm Door on Sixth throughout the day, giving attendees the chance to witness the next generation of personalised nutrition in action and sample bespoke gummy stacks tailored to their individual health goals.
Find out more about Rem3dy Health & Nourished at get-nourished.com
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Pregnancy
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur5 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health






